Table 1.

Clinical Characteristics of IHD Patients and NIHD in the MARK-AGE Study

NIHD, N = 900IHD Patients, N = 86p Value
Age (years)64.3 ± 6.765.5 ± 6.8NS
Males (%)504 (56.6)61 (70.9).010
BMI (kg/m2)26.8 ± 0.128.0 ± 0.5.005
Diabetes, n (%)61 (6.7)15 (17.4).001
Hypertension, n (%)286 (31.7)47 (54.6)<.001
AF, n (%)70 (7.7)20 (23.2)<.001
Previous MI (%)0 (0)37 (43.0)<.001
CRP (μg/L)2.1 ± 0.12.8 ± 0.2.035
NLR1.89 ± 0.031.90 ± 0.10NS
Neutrophils (×103/μL)3.4 ± 0.094.0 ± 0.10NS
Lymphocytes (×103/μL)1.99 ± 0.072.38 ± 0.22NS
Cu/Zn ratio1.57 ± 0.011.69 ± 0.03.001
Total cholesterol (mmol/L)5.68 ± 0.035.13 ± 0.11<.001
LDL cholesterol (mmol/L)3.42 ± 0.032.96 ± 0.10<.001
Triglycerides (mmol/L)1.29 ± 0.031.40 ± 0.08NS
CMV-IgG40.8 ± 1.554.7 ± 4.8.006
NIHD, N = 900IHD Patients, N = 86p Value
Age (years)64.3 ± 6.765.5 ± 6.8NS
Males (%)504 (56.6)61 (70.9).010
BMI (kg/m2)26.8 ± 0.128.0 ± 0.5.005
Diabetes, n (%)61 (6.7)15 (17.4).001
Hypertension, n (%)286 (31.7)47 (54.6)<.001
AF, n (%)70 (7.7)20 (23.2)<.001
Previous MI (%)0 (0)37 (43.0)<.001
CRP (μg/L)2.1 ± 0.12.8 ± 0.2.035
NLR1.89 ± 0.031.90 ± 0.10NS
Neutrophils (×103/μL)3.4 ± 0.094.0 ± 0.10NS
Lymphocytes (×103/μL)1.99 ± 0.072.38 ± 0.22NS
Cu/Zn ratio1.57 ± 0.011.69 ± 0.03.001
Total cholesterol (mmol/L)5.68 ± 0.035.13 ± 0.11<.001
LDL cholesterol (mmol/L)3.42 ± 0.032.96 ± 0.10<.001
Triglycerides (mmol/L)1.29 ± 0.031.40 ± 0.08NS
CMV-IgG40.8 ± 1.554.7 ± 4.8.006

Notes: Data are reported as mean ± standard error of the mean (SEM) or percentages. The laboratory parameter analysis was adjusted for age, sex, countries. AF = atrial fibrillation; BMI = body mass index; CRP = C-reactive protein, Cu/Zn = copper/zinc ratio; CMV = cytomegalovirus; IHD = ischemic heart disease; LDL = low-density lipoprotein; MI = myocardial infarction; NIHD = non-ischemic heart disease; NLR = neutrophil-to-lymphocyte ratio; NS = not significant.

Table 1.

Clinical Characteristics of IHD Patients and NIHD in the MARK-AGE Study

NIHD, N = 900IHD Patients, N = 86p Value
Age (years)64.3 ± 6.765.5 ± 6.8NS
Males (%)504 (56.6)61 (70.9).010
BMI (kg/m2)26.8 ± 0.128.0 ± 0.5.005
Diabetes, n (%)61 (6.7)15 (17.4).001
Hypertension, n (%)286 (31.7)47 (54.6)<.001
AF, n (%)70 (7.7)20 (23.2)<.001
Previous MI (%)0 (0)37 (43.0)<.001
CRP (μg/L)2.1 ± 0.12.8 ± 0.2.035
NLR1.89 ± 0.031.90 ± 0.10NS
Neutrophils (×103/μL)3.4 ± 0.094.0 ± 0.10NS
Lymphocytes (×103/μL)1.99 ± 0.072.38 ± 0.22NS
Cu/Zn ratio1.57 ± 0.011.69 ± 0.03.001
Total cholesterol (mmol/L)5.68 ± 0.035.13 ± 0.11<.001
LDL cholesterol (mmol/L)3.42 ± 0.032.96 ± 0.10<.001
Triglycerides (mmol/L)1.29 ± 0.031.40 ± 0.08NS
CMV-IgG40.8 ± 1.554.7 ± 4.8.006
NIHD, N = 900IHD Patients, N = 86p Value
Age (years)64.3 ± 6.765.5 ± 6.8NS
Males (%)504 (56.6)61 (70.9).010
BMI (kg/m2)26.8 ± 0.128.0 ± 0.5.005
Diabetes, n (%)61 (6.7)15 (17.4).001
Hypertension, n (%)286 (31.7)47 (54.6)<.001
AF, n (%)70 (7.7)20 (23.2)<.001
Previous MI (%)0 (0)37 (43.0)<.001
CRP (μg/L)2.1 ± 0.12.8 ± 0.2.035
NLR1.89 ± 0.031.90 ± 0.10NS
Neutrophils (×103/μL)3.4 ± 0.094.0 ± 0.10NS
Lymphocytes (×103/μL)1.99 ± 0.072.38 ± 0.22NS
Cu/Zn ratio1.57 ± 0.011.69 ± 0.03.001
Total cholesterol (mmol/L)5.68 ± 0.035.13 ± 0.11<.001
LDL cholesterol (mmol/L)3.42 ± 0.032.96 ± 0.10<.001
Triglycerides (mmol/L)1.29 ± 0.031.40 ± 0.08NS
CMV-IgG40.8 ± 1.554.7 ± 4.8.006

Notes: Data are reported as mean ± standard error of the mean (SEM) or percentages. The laboratory parameter analysis was adjusted for age, sex, countries. AF = atrial fibrillation; BMI = body mass index; CRP = C-reactive protein, Cu/Zn = copper/zinc ratio; CMV = cytomegalovirus; IHD = ischemic heart disease; LDL = low-density lipoprotein; MI = myocardial infarction; NIHD = non-ischemic heart disease; NLR = neutrophil-to-lymphocyte ratio; NS = not significant.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close